Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease
Background Neuronal pentraxin-2 (NPTX2), crucial for synaptic functioning, declines in cerebrospinal fluid (CSF) as cognition deteriorates. The variations of CSF NPTX2 across mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and its association with brain metabolism remain elusive, albeit relevant for patient stratification and pathophysiological insights. Methods We retrospectively analyzed 49 MCI-AD patients grouped by time until dementia (EMCI, n = 34 progressing within 2 years; LMCI, n = 15 progressing later/stable at follow-up). We analyzed demographic variables, cognitive status (MMSE score), and CSF NPTX2 levels using a commercial ELISA assay in EMCI, LMCI, and a control group of age-/sex-matched individuals with other non-dementing disorders (OND). Using [18F]FDG PET scans for voxel-based analysis, we explored correlations between regional brain metabolism metrics and CSF NPTX2 levels in MCI-AD patients, accounting for age. Results Baseline and follow-up MMSE scores were lower in LMCI than EMCI (p value = 0.006 and p < 0.001). EMCI exhibited significantly higher CSF NPTX2 values than both LMCI (p = 0.028) and OND (p = 0.006). We found a significant positive correlation between NPTX2 values and metabolism of bilateral precuneus in MCI-AD patients (p < 0.005 at voxel level, p < 0.05 with family-wise error correction at the cluster level). Conclusions Higher CSF NPTX2 in EMCI compared to controls and LMCI suggests compensatory synaptic responses to initial AD pathology. Disease progression sees these mechanisms overwhelmed, lowering CSF NPTX2 approaching dementia. Positive CSF NPTX2 correlation with precuneus glucose metabolism links to AD-related metabolic changes across MCI course. These findings posit CSF NPTX2 as a promising biomarker for both AD staging and progression risk stratification..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:271 |
|---|---|
| Enthalten in: |
Journal of neurology - 271(2023), 4 vom: 29. Dez., Seite 1999-2009 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Massa, Federico [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
[ |
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s00415-023-12154-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055317057 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055317057 | ||
| 003 | DE-627 | ||
| 005 | 20240328072117.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240328s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00415-023-12154-7 |2 doi | |
| 035 | |a (DE-627)SPR055317057 | ||
| 035 | |a (SPR)s00415-023-12154-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.90 |2 bkl | ||
| 100 | 1 | |a Massa, Federico |e verfasserin |0 (orcid)0000-0001-5667-204X |4 aut | |
| 245 | 1 | 0 | |a Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Background Neuronal pentraxin-2 (NPTX2), crucial for synaptic functioning, declines in cerebrospinal fluid (CSF) as cognition deteriorates. The variations of CSF NPTX2 across mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and its association with brain metabolism remain elusive, albeit relevant for patient stratification and pathophysiological insights. Methods We retrospectively analyzed 49 MCI-AD patients grouped by time until dementia (EMCI, n = 34 progressing within 2 years; LMCI, n = 15 progressing later/stable at follow-up). We analyzed demographic variables, cognitive status (MMSE score), and CSF NPTX2 levels using a commercial ELISA assay in EMCI, LMCI, and a control group of age-/sex-matched individuals with other non-dementing disorders (OND). Using [18F]FDG PET scans for voxel-based analysis, we explored correlations between regional brain metabolism metrics and CSF NPTX2 levels in MCI-AD patients, accounting for age. Results Baseline and follow-up MMSE scores were lower in LMCI than EMCI (p value = 0.006 and p < 0.001). EMCI exhibited significantly higher CSF NPTX2 values than both LMCI (p = 0.028) and OND (p = 0.006). We found a significant positive correlation between NPTX2 values and metabolism of bilateral precuneus in MCI-AD patients (p < 0.005 at voxel level, p < 0.05 with family-wise error correction at the cluster level). Conclusions Higher CSF NPTX2 in EMCI compared to controls and LMCI suggests compensatory synaptic responses to initial AD pathology. Disease progression sees these mechanisms overwhelmed, lowering CSF NPTX2 approaching dementia. Positive CSF NPTX2 correlation with precuneus glucose metabolism links to AD-related metabolic changes across MCI course. These findings posit CSF NPTX2 as a promising biomarker for both AD staging and progression risk stratification. | ||
| 650 | 4 | |a Cerebrospinal fluid biomarkers |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a [ |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a F]FDG PET |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Synaptic dysfunction |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Mild cognitive impairment (MCI) |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Alzheimer's disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neuronal pentraxin-2 |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Martinuzzo, Caterina |4 aut | |
| 700 | 1 | |a Gómez de San José, Nerea |4 aut | |
| 700 | 1 | |a Pelagotti, Virginia |4 aut | |
| 700 | 1 | |a Kreshpa, Wendy |4 aut | |
| 700 | 1 | |a Abu-Rumeileh, Samir |4 aut | |
| 700 | 1 | |a Barba, Lorenzo |4 aut | |
| 700 | 1 | |a Mattioli, Pietro |4 aut | |
| 700 | 1 | |a Orso, Beatrice |4 aut | |
| 700 | 1 | |a Brugnolo, Andrea |4 aut | |
| 700 | 1 | |a Girtler, Nicola |4 aut | |
| 700 | 1 | |a Vigo, Tiziana |4 aut | |
| 700 | 1 | |a Arnaldi, Dario |4 aut | |
| 700 | 1 | |a Serrati, Carlo |4 aut | |
| 700 | 1 | |a Uccelli, Antonio |4 aut | |
| 700 | 1 | |a Morbelli, Silvia |4 aut | |
| 700 | 1 | |a Chincarini, Andrea |4 aut | |
| 700 | 1 | |a Otto, Markus |4 aut | |
| 700 | 1 | |a Pardini, Matteo |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neurology |d Springer Berlin Heidelberg, 1891 |g 271(2023), 4 vom: 29. Dez., Seite 1999-2009 |w (DE-627)SPR005310695 |w (DE-600)1421299-7 |x 1432-1459 |7 nnns |
| 773 | 1 | 8 | |g volume:271 |g year:2023 |g number:4 |g day:29 |g month:12 |g pages:1999-2009 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00415-023-12154-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.90 |q VZ |
| 951 | |a AR | ||
| 952 | |d 271 |j 2023 |e 4 |b 29 |c 12 |h 1999-2009 | ||